Bayer wants to amend Xarelto patent at centre of Sandoz’s invalidity claim
Ashurst
2022-07-15 11:37 am
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
For information on rights and reprints, contact subscriptions@lawyerly.com.au